{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:11:44Z","timestamp":1767917504304,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002888","name":"Beijing Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clinbiochem.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:14:31Z","timestamp":1647897271000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Current status of therapeutic drug monitoring for methotrexate, imatinib, paclitaxel in China"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4174-6047","authenticated-orcid":false,"given":"Weiyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinbiochem.2022.03.005_b0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11523-017-0486-5","article-title":"Gemcitabine in combination with a second cytotoxic agent in the first-line treatment of locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2017","journal-title":"Target. Oncol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.03.005_b0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/atm.2017.10.29","article-title":"Current therapeutic landscape for advanced gastroesophageal cancers","volume":"6","author":"Lopez","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.03.005_b0015","first-page":"D6875","article-title":"Second-line systemic therapy for metastatic colorectal cancer","volume":"1","author":"Mocellin","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.03.005_b0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","article-title":"Therapeutic drug monitoring in cancer\u2013are we missing a trick?","volume":"50","author":"Bardin","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.03.005_b0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/FTD.0000000000000701","article-title":"Cancer chemotherapy: the case for therapeutic drug monitoring","volume":"42","author":"Knezevic","year":"2020","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.03.005_b0030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4155\/bio.10.48","article-title":"Therapeutic drug monitoring in cancer chemotherapy","volume":"2","author":"Bach","year":"2010","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.03.005_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/clinchem\/44.2.375","article-title":"Analytical goals in therapeutic drug monitoring","volume":"44","author":"Bowers","year":"1998","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.03.005_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"issue":"11","key":"10.1016\/j.clinbiochem.2022.03.005_b0045","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","article-title":"Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates","volume":"48","author":"Hryniuk","year":"1969","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.03.005_b0050","first-page":"1141","article-title":"Chemotherapy of cancer of the head and neck","volume":"31","author":"Bertino","year":"1973","journal-title":"Cancer-Am. Cancer Soc."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.03.005_b0055","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bjc.6603273","article-title":"Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells","volume":"95","author":"Sinha","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.03.005_b0060","first-page":"1246","article-title":"Methotrexate: an active drug in bladder cancer","volume":"47","author":"Natale","year":"1981","journal-title":"Cancer-Am. Cancer Soc."},{"key":"10.1016\/j.clinbiochem.2022.03.005_b0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s13075-015-0814-z","article-title":"Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study","volume":"17","author":"Hawwa","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.03.005_b0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13555-014-0056-z","article-title":"Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature","volume":"4","author":"Weidmann","year":"2014","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"27","key":"10.1016\/j.clinbiochem.2022.03.005_b0075","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJMc1507547","article-title":"Acute methotrexate-induced crystal nephropathy","volume":"373","author":"Garneau","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.clinbiochem.2022.03.005_b0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.clinbiochem.2022.03.005_b0085","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.03.005_b0090","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two\u2013targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.03.005_b0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.03.005_b0100","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"23","author":"Hitt","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2022.03.005_b0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/IJWH.S7012","article-title":"Clinical trials and progress with paclitaxel in ovarian cancer","volume":"2","author":"Kumar","year":"2010","journal-title":"Int. J. Womens Health"},{"issue":"10","key":"10.1016\/j.clinbiochem.2022.03.005_b0110","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdw290","article-title":"Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"27","author":"Joerger","year":"2016","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.03.005_b0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/CAD.0000000000000093","article-title":"Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel\u2013a review","volume":"25","author":"de Weger","year":"2014","journal-title":"Anticancer Drugs"},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.03.005_b0120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/14622416.8.7.803","article-title":"Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel","volume":"8","author":"Steed","year":"2007","journal-title":"Pharmacogenomics"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:58:42Z","timestamp":1757865522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912022000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":24,"alternative-id":["S0009912022000790"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.03.005","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of therapeutic drug monitoring for methotrexate, imatinib, paclitaxel in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}